Loading
A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04980885 by Akeso, with 68 participants enrolled, started 2021-08-13 and due to reach its primary completion in 2025-09. Interventions recorded: AK117 and Azacitidine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/